Glaukos Corporation (GKOS)
| Previous Close | 107.98 |
| Open | 107.09 |
| Bid | 106.10 x 900 |
| Ask | 106.51 x 900 |
| Day's Range | 105.22 - 107.45 |
| 52 Week Range | 54.38 - 110.73 |
| Volume | |
| Avg. Volume | 520,865 |
| Market Cap | 5.37B |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Glaukos Announces First Quarter 2024 Financial Results
ALISO VIEJO, Calif., May 01, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include:
- Business Wire
Glaukos Announces the Release of its 2023 Sustainability Report
ALISO VIEJO, Calif., April 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website here.
- Business Wire
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
ALISO VIEJO, Calif., April 10, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024.
